<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font21 { font-size : 21; } .font24 { font-size : 24; } .font28 { font-size : 28; } .font30 { font-size : 30; }</style>
 <body>
  <p>
   <span class="font30">migraine </span>
   <span class="font28">galcanezumab </span>
   <span class="font24">patients </span>
   <span class="font21">(.%) </span>
   <span class="font19">placebo </span>
   <span class="font18">(%) </span>
   <span class="font18">treatment </span>
   <span class="font17">Galcanezumab </span>
   <span class="font16">CGRP </span>
   <span class="font16">MHD </span>
   <span class="font15">&amp;lt;. </span>
   <span class="font15">clinical </span>
   <span class="font15">study </span>
   <span class="font15">trial </span>
   <span class="font15">(S) </span>
   <span class="font15">EVOLVE- </span>
   <span class="font15">efficacy </span>
   <span class="font14">Phase </span>
   <span class="font14">migraine: </span>
   <span class="font14">significant </span>
   <span class="font14">response </span>
   <span class="font14">headache </span>
   <span class="font14">{border-style </span>
   <span class="font14">(n= </span>
   <span class="font14">Headache </span>
   <span class="font14">episodic </span>
   <span class="font14">gene-related </span>
   <span class="font13">Neurol </span>
   <span class="font13">peptide </span>
   <span class="font13">preventive </span>
   <span class="font13">px;} </span>
   <span class="font13">#ffffff;} </span>
   <span class="font13">acute </span>
   <span class="font13">baseline </span>
   <span class="font13">chronic </span>
   <span class="font13">monthly </span>
   <span class="font13">results </span>
   <span class="font13">days </span>
   <span class="font13">randomized </span>
   <span class="font13">Dodick </span>
   <span class="font13">III </span>
   <span class="font13">calcitonin </span>
   <span class="font13">compared </span>
   <span class="font13">data </span>
   <span class="font13">Cephalalgia </span>
   <span class="font13">capsaicin-induced </span>
   <span class="font13">double-blind, </span>
   <span class="font13">phase </span>
   <span class="font12">prevention </span>
   <span class="font12">(NCT) </span>
   <span class="font12">(n=) </span>
   <span class="font12">P-value </span>
   <span class="font12">doses </span>
   <span class="font12">mean </span>
   <span class="font12">safety </span>
   <span class="font12">â€ƒInjection-site </span>
   <span class="font12">EVOLVE-, </span>
   <span class="font12">Table </span>
   <span class="font12">blood </span>
   <span class="font12">month </span>
   <span class="font12">pain </span>
   <span class="font12">placebo-controlled </span>
   <span class="font12">primary </span>
   <span class="font12">randomized, </span>
   <span class="font12">receptor </span>
   <span class="font12">statistically </span>
   <span class="font12">therapy </span>
   <span class="font12">trials </span>
   <span class="font12">use </span>
   <span class="font12">Migraine </span>
   <span class="font12">Pharmacol </span>
   <span class="font12">collab: </span>
   <span class="font12">dose </span>
   <span class="font12">reduction </span>
   <span class="font11">Goadsby </span>
   <span class="font11">Lancet </span>
   <span class="font11">Placebo </span>
   <span class="font11">REGAIN </span>
   <span class="font11">administered </span>
   <span class="font11">adults </span>
   <span class="font11">antibody </span>
   <span class="font11">migraine. </span>
   <span class="font11">months </span>
   <span class="font11">patients, </span>
   <span class="font11">prophylaxis </span>
   <span class="font11">reported </span>
   <span class="font11">studies </span>
   <span class="font11">treatment-emergent </span>
   <span class="font11">trials, </span>
   <span class="font11">(.) </span>
   <span class="font11">(eg, </span>
   <span class="font11">-month </span>
   <span class="font11">DBF </span>
   <span class="font11">EM, </span>
   <span class="font11">Study </span>
   <span class="font11">adherence </span>
   <span class="font11">administration </span>
   <span class="font11">adverse </span>
   <span class="font11">associated </span>
   <span class="font11">binding </span>
   <span class="font11">change </span>
   <span class="font11">double-blind </span>
   <span class="font11">medication </span>
   <span class="font11">number </span>
   <span class="font11">prophylactic </span>
   <span class="font11">px; </span>
   <span class="font11">secondary </span>
   <span class="font11">similar </span>
   <span class="font11">study, </span>
   <span class="font11">subcutaneous </span>
   <span class="font11">time </span>
   <span class="font11">years </span>
   <span class="font11">{font-family </span>
   <span class="font11">Accessed </span>
   <span class="font11">Available </span>
   <span class="font11">Med </span>
   <span class="font11">Neurology </span>
   <span class="font11">TEAEs </span>
   <span class="font11">affected </span>
   <span class="font11">antibodies </span>
   <span class="font11">available </span>
   <span class="font11">controlled </span>
   <span class="font11">differences </span>
   <span class="font11">drugs </span>
   <span class="font11">effect </span>
   <span class="font11">font-size </span>
   <span class="font11">frequency </span>
   <span class="font11">from: </span>
   <span class="font11">improvement </span>
   <span class="font11">low </span>
   <span class="font11">monoclonal </span>
   <span class="font11">open-label </span>
   <span class="font11">randomised, </span>
   <span class="font11">release </span>
   <span class="font11">therapies </span>
   <span class="font11">treatment. </span>
   <span class="font11">(NCT), </span>
   <span class="font11">(ie, </span>
   <span class="font11">Aurora </span>
   <span class="font11">Bigal </span>
   <span class="font11">CM. </span>
   <span class="font11">Calcitonin </span>
   <span class="font11">Clin </span>
   <span class="font11">Company </span>
   <span class="font11">Eli </span>
   <span class="font11">Lilly </span>
   <span class="font11">Lipton </span>
   <span class="font11">Rev </span>
   <span class="font11">Safety </span>
   <span class="font11">Text </span>
   <span class="font11">adult </span>
   <span class="font11">analysis </span>
   <span class="font11">assessed </span>
   <span class="font11">barrier </span>
   <span class="font11">consecutive </span>
   <span class="font11">development </span>
   <span class="font11">did </span>
   <span class="font11">double; </span>
   <span class="font11">drug </span>
   <span class="font11">endpoint </span>
   <span class="font11">flow </span>
   <span class="font11">galcanezumab, </span>
   <span class="font11">galcanezumab-treated </span>
   <span class="font11">group </span>
   <span class="font11">injection-site </span>
   <span class="font11">mg) </span>
   <span class="font11">mg, </span>
   <span class="font11">model </span>
   <span class="font11">multiplicity </span>
   <span class="font11">period. </span>
   <span class="font11">placebo-controlled, </span>
   <span class="font11">placebo. </span>
   <span class="font11">post </span>
   <span class="font11">review </span>
   <span class="font11">significantly </span>
   <span class="font11">single </span>
   <span class="font11">therapeutic </span>
   <span class="font11">tract </span>
   <span class="font11">treated </span>
   <span class="font11">trigeminal </span>
   <span class="font11">August </span>
   <span class="font11">Brain </span>
   <span class="font11">CGRP, </span>
   <span class="font11">CGRP. </span>
   <span class="font11">ClinicalTrials.gov </span>
   <span class="font11">Curr </span>
   <span class="font11">Edvinsson </span>
   <span class="font11">MAbs, </span>
   <span class="font11">Negro </span>
   <span class="font11">P&amp;lt;. </span>
   <span class="font11">Pain </span>
   <span class="font11">Silberstein </span>
   <span class="font11">View </span>
   <span class="font11">Zhang </span>
   <span class="font11">anti-CGRP </span>
   <span class="font11">attacks </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">cardiovascular </span>
   <span class="font11">cluster </span>
   <span class="font11">conducted </span>
   <span class="font11">days) </span>
   <span class="font11">demonstrated </span>
   <span class="font11">different </span>
   <span class="font11">disability </span>
   <span class="font11">early </span>
   <span class="font11">effects </span>
   <span class="font11">estimated </span>
   <span class="font11">evidence </span>
   <span class="font11">following </span>
   <span class="font11">functional </span>
   <span class="font11">greater </span>
   <span class="font11">groups </span>
   <span class="font11">hoc </span>
   <span class="font11">https://clinicaltrials.gov/ct/show/NCT </span>
   <span class="font11">inhibition </span>
   <span class="font11">key </span>
   <span class="font11">meaningful </span>
   <span class="font11">mechanism </span>
   <span class="font11">peripheral </span>
   <span class="font11">placebo, </span>
   <span class="font11">prefilled </span>
   <span class="font11">responses </span>
   <span class="font11">solid; </span>
   <span class="font11">tolerability </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font10">(.% </span>
   <span class="font10">(NS) </span>
   <span class="font10">AEs </span>
   <span class="font10">Abbreviations: </span>
   <span class="font10">Accordingly, </span>
   <span class="font10">Chronic </span>
   <span class="font10">Efficacy </span>
   <span class="font10">Importantly, </span>
   <span class="font10">MAb </span>
   <span class="font10">MAbs </span>
   <span class="font10">MHD, </span>
   <span class="font10">Monthly </span>
   <span class="font10">Multinational </span>
   <span class="font10">Participants </span>
   <span class="font10">Patients </span>
   <span class="font10">Risk </span>
   <span class="font10">Skljarevski </span>
   <span class="font10">Stauffer </span>
   <span class="font10">Ther </span>
   <span class="font10">achieved </span>
   <span class="font10">action </span>
   <span class="font10">adjustment. </span>
   <span class="font10">and, </span>
   <span class="font10">autoinjector </span>
   <span class="font10">bold </span>
   <span class="font10">clinically </span>
   <span class="font10">considered </span>
   <span class="font10">considering </span>
   <span class="font10">courier; </span>
   <span class="font10">current </span>
   <span class="font10">daily </span>
   <span class="font10">dermal </span>
   <span class="font10">does </span>
   <span class="font10">em; </span>
   <span class="font10">endpoints </span>
   <span class="font10">evaluation </span>
   <span class="font10">events </span>
   <span class="font10">galcanezumab. </span>
   <span class="font10">headache: </span>
   <span class="font10">healthy </span>
   <span class="font10">increase </span>
   <span class="font10">involvement </span>
   <span class="font10">levels </span>
   <span class="font10">long-term, </span>
   <span class="font10">max </span>
   <span class="font10">mg; </span>
   <span class="font10">migraine, </span>
   <span class="font10">months, </span>
   <span class="font10">observed </span>
   <span class="font10">patients. </span>
   <span class="font10">place </span>
   <span class="font10">preventing </span>
   <span class="font10">previous </span>
   <span class="font10">profile </span>
   <span class="font10">provided </span>
   <span class="font10">pt;} </span>
   <span class="font10">rate </span>
   <span class="font10">reduced </span>
   <span class="font10">reductions </span>
   <span class="font10">relevant </span>
   <span class="font10">respiratory </span>
   <span class="font10">sensory </span>
   <span class="font10">showed </span>
   <span class="font10">sodium </span>
   <span class="font10">specific </span>
   <span class="font10">statistical </span>
   <span class="font10">studied </span>
   <span class="font10">studies, </span>
   <span class="font10">suicidal </span>
   <span class="font10">syringe </span>
   <span class="font10">target </span>
   <span class="font10">targeting </span>
   <span class="font10">terms </span>
   <span class="font10">that, </span>
   <span class="font10">treatments </span>
  </p>
 </body>
</html>
